Safety of recombinant human growth hormone in treating children with growth hormone deficiency and idiopathic short stature.
10.3881/j.issn.1000-503X.2011.02.005
- Author:
Shu CHANG
1
;
Pan HUI
Author Information
1. Department of Endocrinology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Dwarfism;
drug therapy;
Dwarfism, Pituitary;
drug therapy;
Human Growth Hormone;
adverse effects;
deficiency;
therapeutic use;
Humans;
Recombinant Proteins;
adverse effects;
therapeutic use
- From:
Acta Academiae Medicinae Sinicae
2011;33(2):123-126
- CountryChina
- Language:English
-
Abstract:
Recombinant human growth hormone is generally safe in treating children with growth hormone deficiency and idiopathic short stature. However, side effects such as sodium and water retention, benign intracranial hypertension, insulin insensitivity, increasing risk of secondary neoplasm, scoliosis, and slipped capital femoral epiphysis may occur occasionally, although the overall incidence remains low.
